These results demonstrated that circLIFR could upregulate GSK-3β expression and inactivate the Wnt/β-catenin signaling pathway, thereby expanding the knowledge about the molecular mechanism of HCC progression. This evidence concerns the gene GSK3B and hepatocellular carcinoma.